Abigail Brooks, MA

Data from the phase 1 trial are intended to support dosing in a planned phase 2 trial in kidney transplant recipients.

Findings suggest the value of genotyping and histological assessment for guiding HCC screening decisions in patients with chronic HBV.

Findings from the LIVERHOPE trial suggest adding simvastatin and rifaximin to standard therapy does not reduce ACLF occurrence.

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

Laique reviews data supporting the use of metabolic surgery in patients with obesity and cirrhotic MASH.

Laique emphasizes the unmet needs for patients with cirrhotic MASH who are not eligible for resmetirom and what role metabolic surgery may play in their care.

The month in review spotlights the top news and research in nephrology from January, including an FDA approval and new IgAN research.

Findings call attention to age-related neurodevelopmental differences between pediatric patients with CKD and healthy controls.

United Therapeutics’ investigational UKidney is derived from a 10 gene-edited source pig and will be tested in a clinical study of ESRD patients.

This month in review spotlights HCPLive’s coverage of hepatic pipeline news and recent research about MASLD, liver transplant, and alcohol in liver disease.

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

Greater magnesium depletion scores were longitudinally linked to increased risks for all-cause and CVD mortality in patients with MASLD or MetALD.

Although FIB-4, ELF, and VCTE LSM performance did not vary significantly by patient characteristics, threshold adjustment was needed.

Garimella describes the overlap between diabetes and kidney disease, explaining the significance of semaglutide’s new indication for these patients.

The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.

Findings suggest the benefits of combined belatacept and tacrolimus immunosuppression after kidney transplantation for patient and all-cause graft survival.

Study findings suggest NMP is especially beneficial for DCD allografts and is linked to better outcomes and resource use than SCS.

Findings suggest MASLD, especially with diabetes, overweight, or hypertension, is associated with significant fibrosis in patients with HCV.

The FDA approved semaglutide to reduce the risk of kidney disease worsening, kidney failure, and death due to CVD in those with T2D and CKD.

Patients who started dialysis as children but were not waitlisted until young adulthood faced worse outcomes than those who were listed before turning 18.

Compared with nonsurgical treatment, metabolic surgery was associated with reduced risks of incident MALO and progression to decompensation.

Results showed no difference in time to relapse, relapse rates, subsequent immunosuppression use, or kidney function between the medications.

Preliminary topline week 96 results showed statistically significant reversal of MASH compensated cirrhosis with efruxifermin in complete and ITT analyses.

Greater levels of physical activity and higher diet quality were linked to a reduced risk of MASLD, MetALD, and compensated advanced chronic liver disease.

Donor HCV positivity was not associated with acute rejection or recipient mortality 1-year post-renal transplant in HCV-negative recipients.

The updated clinical practice guideline addresses new research and clinical developments since the first iteration of the guideline was released in 2014.

Factors associated with 30-day readmission were shorter hospital stays after transplant, insurance status, and patient history of diabetes and malignancy.

MASLD and MetALD were linked to a greater risk of incident IBD, with risk increasing as the number of associated cardiometabolic risk factors increased.

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.